Maximizing efficiency of identify the

the hidden cause inherited disorder

and shape safer family

Accelerated Making Clinical Decision

with Omics Data

TAIGenomics is a cloud platform that aims to speed up multi-omics analyses using AI and bioinformatic solution. Using TAIGenomics, you can easily analyze genomic, transcriptomic and proteomic data using standardized processes and customized workflow in one place.

Product Features

Entity normalization

Find and normalize entities from publications and query inputs to provide comprehensive and precise results

Knowledge graph

Extract relationships between any biomedical entities to provide biological relations using knowledge graph

Updated publication

Automatically extracted with regular updates from full text of PubMed articles


Copyright © 2021 TAIGenomics. All Rights Reserved.

1. Use of Standards in FDA Regulatory Oversight of Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Used for Diagnosing Germline Diseases. FDA, Jul. 2016

2. Use of Public Human Genetic Variant Databases to Support Clinical Validity for Next Generation Sequencing (NGS)-Based In Vitro Diagnostics. FDA, Jul. 2016

3. Clinical laboratory standards for next-generation sequencing. ACMG, Sep. 2013.

4. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. ACMG, Mar. 2015.

5. Good laboratory practice for clinical next-generation sequencing informatics pipelines. CDC, Jul. 2015.

6. Guidelines for Validation of Next-Generation Sequencing Based Oncology Panels. AMP/CAP, May. 2017.

7. "Next Generation" Sequencing (NGS) guidelines for somatic genetic variant detection. NYSDOH, Mar. 2015.

8. Guidelines for diagnostic next-generation sequencing. EuroGentest, Oct. 2015.

9. Assuring the Quality of Next-Generation Sequencing in Clinical Laboratory Practice. CDC, Nov. 2012.

Contact us